The role of aspirin in cardiovascular diseases – forgotten benefits?

Bibliography

• AMERICAN HEART ASSOCIATION: Heart Disease and Stroke Statistics - 2003 Update. American Heart Association, Dallas, Texas (2002).
   Google Scholar
• EUROPEAN CARDIOVASCULAR DISEASE STATISTICS: 2000 Edition, British Heart Foundation.
   Google Scholar
• CHOCKALINGA M A, BALAGUER-VINTRO I: Impending global pandemic of cardiovascular diseases. Prous Science, Barcelona, Spain (1999).
   Google Scholar
• MURRAY CJL, LOPEZ AD: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and Projected to 2020. Harvard University Press, Cambridge, Massachusetts, USA (1996).
   Google Scholar
• HENNEKENS CH: Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation (1998) 97:1095–1102.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, ALBERT CM, GODFRIED SL, GAZIANO JM, BURING JE: Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl. J. Med. (1996) 335:1660–1668.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, BLAIR SN, DANIELS SR et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. Circulation (2002) 106:388–391.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, BURING JE: Epidemiology M Medicine. Little, Brown & Co, Boston, Massachusetts, USA (1987).
   Google Scholar
• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231:232–235.
   PubMedGoogle Scholar
• BOSTON COLLABORATIVE DRUG SURVEILLANCE GROUP: Regular aspirin intake and acute myocardial infarction. Br. Med. J. (1974) 1:440–443.
   PubMed Web of Science ®Google Scholar
• JICK H, MIETTINEN OS: Regular aspirin use and myocardial infarction. Br. Med. J. (1976) 1:1057.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, KARLSON LK, ROSNER B: A case control study of regular aspirin use and coronary deaths. Circulation (1978) 58:35–38.
   PubMedGoogle Scholar
• MANSON JE, STAMPFER MJ, COLDITZ GA et al.: A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA (1991) 266:521–527.
   PubMed Web of Science ®Google Scholar
• HAMMOND EC, GARFINKEL L: Aspirin and coronary heart disease: findings of a prospective study. Br. Med. J. (1975) 2:269–271.
   PubMedGoogle Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomized trials of ant platelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• EIDELMAN RS, HEBERT PR, WEISMAN S, HENNEKENS CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch. Intern. Med. (2003) 163(17):2006–2010.
   PubMedGoogle Scholar
• FRIEDMAN LM, FURBERG CD, DEMETS DL: Fundamentals of Clinical Trials. Springer-Verlag, New York, New York, 1998.
   Google Scholar
• ANITPLATELET TRIALISTS COLLABORATION: Secondary prevention of vascular disease by prolonged anti-platelet therapy. Br. Med. J. (1988) 296:320–332.
   PubMedGoogle Scholar
• ANTIPLATELET TRIALISTS COLLABORATION: Collaborative overview of randomized trials of ant platelet treatment. Part I: Prevention of vascular death, myocardial infarction and stroke by prolonged ant platelet therapy in different categories of patients. Br. Med. J. (1994) 308:81–106.
   Google Scholar
• ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS2. Lancet (1988) 2:349–360.
   PubMed Web of Science ®Google Scholar
• FITZGERALD DJ, CATELLA F, ROY L, FITZGERALD GA: Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation (1988) 77:142–150.
   PubMed Web of Science ®Google Scholar
• BAIGENT C, COLLINS R, APPLEBY P, PARISH S, SLEIGHT P, PETO R: ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. Br. Med. J. (1998) 316:1337–1343.
   PubMed Web of Science ®Google Scholar
• LAMAS GA, PFEFFER MA, HAMM P, WERTHEIMER J, ROULEAU JL, BRAUNWALD E: Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl. J. Med. (1992) 327:241–247.
   Google Scholar
• STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl. Med. (1989) 321:129–135.
   PubMed Web of Science ®Google Scholar
• PETO R, GRAY R, COLLINS R et al.: Randomized trial of prophylactic daily aspirin in British male doctors. Br. Med. (1988) 296:313–316.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, PETO R, HUTCHISON GB, DOLL R: An overview of the British and American aspirin studies. Correspondence. N Engl. I Med. (1988) 318:923–924.
   PubMed Web of Science ®Google Scholar
• THE MEDICAL RESEARCH COUNCIL'S GENERAL PRACTICE RESEARCH FRAMEWORK: Thrombosis prevention trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet (1998) 351:233–240.
   PubMed Web of Science ®Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE GROUP OF THE PRIMARY PREVENTION PROJECT: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet (2001) 357:89–95
   PubMed Web of Science ®Google Scholar
• SANMUGANATHAN PS, GHAHRAMANI P, JACKSON PR, WALLIS EJ, RAMSAY IE: Aspirin for primary prevention of coronary heart disease, safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart (2001) 85:265–271.
   PubMed Web of Science ®Google Scholar
• US PREVENTIVE SERVICES TASK FORCE: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann. Intern. Med. (2002) 136:157–60.
   PubMedGoogle Scholar
• FITZGERALD GA, LUPINETTI M, CHARMAN SA, CHARMAN WN: Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. .1 Pharmacol Exp. Ther. (1991) 259(3):1043–1049.
   Google Scholar
• HENNEKENS CH, BURING JE, SANDERCOCK P, COLLINS R, PETO R: Aspirin and other ant platelet agents in the secondary and primary prevention of cardiovascular disease. Circulation (1989) 80:749–756.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, DYKEN ML, FUSTER V: Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1997) 96:2751–2753.
   PubMed Web of Science ®Google Scholar
• SMITH SC, BLAIR SN, BONOW RO, BRASS LM et al.: AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update: A statement for healthcare professionals form the American Heart Association and American College of Cardiology. Circulation (2001) 104:157–160.
   PubMedGoogle Scholar
• HEBERT PR, PFEFFER MA, HENNEKENS CH: Additive benefits of aspirin and statins. Cardiovasc. Pharmacol Ther: (2002) 7: 77
   PubMedGoogle Scholar
• HENNEKENS CH, SACKS F, TONKIN A et al.: Additive benefits of pravastatin and aspirin to reduce risks of cardiovascular disease. Arch. Int. Med. (2003) (In Press).
   Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl. I Med. (1997) 336:973–979.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl. J. Med. (2000) 342:836–843.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, SCHROR K, WEISMAN S, FITZGERALD GA: Semantic complexity and aspirin resistance. Circulation (2003) (Submitted).
   Google Scholar
• NELSON M, REID C, MCNEIL J: Rationale for a primary prevention trial of low dose aspirin for major adverse cardiovascular events and vascular dementia in the elderly. ASPirin in Reducing Events in the Elderly (ASPREE), Drugs Aging (2003) (In Press).
   Google Scholar
• BURING JE, HENNEKENS CH FOR THE WOMEN'S HEALTH STUDY RESEARCH GROUP. THE WOMEN'S HEALTH STUDY: Summary of the design J. Myocardial. Ischemia (1992) 4:27–29
   Google Scholar
• AMERICAN Diabetes Association: aspirin therapy in diabetes Diabetes Care (2000) 23\(Suppl. 1):561.
   Google Scholar
• http://www.medscape.com/medscape/ GeneralMedicine/journa1/1999/v01.n11/ mgm1122.cook/mgm1122. cook-01. html COOK NR, CHAE CU, MUELLER FB, LANDIS S, SAKS AM, HENNEKENS CH: Mismedication and underutilization of aspirin in the prevention and treatment of cardiovascular disease. MedGenMed (1999).
   Google Scholar